💊 Sanofi teams up with Egypt’s Minapharm; BMS’s new $8.4 billion ADC deal; Daewoong sells depot injection rights to Zydus

#491 | All things AMA; Seeking transparency from CEPI; Sgt. Pepper’s Unhealthy Hearts Club Band

Hello, and welcome back to The Kable, where the UN chief is imploring the talking heads at COP28 for action to phase out fossil fuels, and Germany is saying it can't sign on to a draft that doesn't include a fossil fuel phase-out plan. All this while the COP28 draft doesn't mention any phase-out of fossil fuels, no doubt making the oil chief in charge very happy.

The number of countries in Africa reporting an anthrax outbreak has swelled to five, with Kenya, Malawi and Zimbabwe joining Uganda and Zambia.

Four months ago, GSK exited Nigeria, citing poor economic conditions as one of its reasons to do so. Since then, drug prices in Nigeria have touched astronomical levels, with people increasingly resorting to herbal concoctions. Enthused by that success, GSK is now exiting Kenya as well.

Counterfeit drugs are a major issue across the African continent. This CNBC exposé reveals how the biz works and what Big Pharma is doing to fight back.

Egypt's local manufacturing plans have gotten another big shot in the arm with the announcement that Sanofi is partnering with local drugmaker Minapharm to increase production of the widely-used anticoagulant Clexane in Egypt.

Last month in Saudi Arabia, the Saudi Food and Drug Authority identified 52 pharma facilities for non-compliance related to drug supply and tracking, imposing penalties of about SR1.3 million.

South Korea's Daewoong Pharma has sold the rights for clinical development and commercialisation of its DWJ108U Depot injection to UAE-based Zydus Worldwide DMCC for the US market in a $92.38 million deal, which includes milestones and supply contracts.

Bristol Myers Squibb will pay $800 million upfront and potentially up to $8.4 billion to Sichuan Biokin Pharmaceutical's unit SystImmune to develop and commercialise a promising antibody-drug conjugate (ADC) cancer treatment outside China. The deal includes contingent payments of up to $500 million for co-development, and additional milestones of up to $7.1 billion, with SystImmune handling development and commercialisation in mainland China and Bristol Myers in other regions.

And finally, 900. That is how many seals and sea lions in Brazil have succumbed to bird flu.